Download this press release (153 KB).
ROSEVILLE, MN (February 6, 2017) — Rebiotix Inc., a clinical-stage biotechnology company focused on harnessing the power of the human microbiome to treat challenging diseases, today announced that it will present at the BIO CEO & Investor Conference being held February 13-14, 2017, at the Waldorf Astoria in New York City.
Lee Jones, co-founder, president and CEO, will present Rebiotix’s corporate growth strategy and its position as the most clinically advanced microbiome company in the industry. Topics in the presentation will include a review of Rebiotix’s pioneering Microbiota Restoration Therapy (MRT) platform and its drug development pipeline, which includes RBX2660, the company’s Phase 3-ready drug candidate for the prevention of recurrent Clostridium difficile (C. diff.) infection, as well as RBX7455, a lyophilized non-frozen oral capsule formulation being evaluated in a Phase 1 clinical study for the prevention of recurrent C. diff. infection.
Event: BIO CEO & Investor Conference
Date: Monday. February 13, 2017
Time: 3:00 p.m. (Eastern Time)
Location: The Waldorf Astoria – Park North Room
About Rebiotix Inc.
Rebiotix Inc. is a clinical-stage biotechnology company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix is the most clinically advanced microbiome company in the industry, with its Phase 3-ready drug candidate, RBX2660, having completed a Phase 2b randomized, double-blind, placebo-controlled trial for prevention of recurrent Clostridium difficile (C. diff.) infection (PUNCH™ CD2). RBX2660 has been granted Orphan Drug status, Fast Track status and Breakthrough Therapy Designation from the FDA for its potential to prevent recurrent C. diff. infection. Rebiotix’s development pipeline includes multiple formulations targeting several disease indications and is built around its pioneering Microbiota Restoration Therapy (MRT) platform. MRT is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad spectrum of live microbes into a patient’s intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.
Rebiotix Media Contact:
Tiberend Strategic Advisors